Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease

被引:47
作者
Ebadi, Manuchair
Sharma, Sushil
机构
[1] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol, Grand Forks, ND 58203 USA
[2] Univ N Dakota, Sch Med & Hlth Sci, Dept Clin Neurosci, Grand Forks, ND 58203 USA
[3] Univ N Dakota, Sch Med & Hlth Sci, Ctr Excellence Neurosci, Cyclotron & Positron Imaging Res Lab, Grand Forks, ND 58203 USA
关键词
metallothioneins; 3-morpholinosydnonimine; ONOO-; alpha-synuclein; dopamine; caspase-3; apoptosis; transplantation; F-18-DOPA; Parkinson disease; NITRIC-OXIDE; NEUROPROTECTIVE ACTIONS; BRAIN METALLOTHIONEIN; COENZYME Q(10); METAL RELEASE; CELLS; ZINC; MICE; PATHOGENESIS; SELEGILINE;
D O I
10.1177/153537020623100919
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We have examined potent peroxynitrite ion (ONOO-) generator 3-morpholinosydnonimine (SIN-1)-induced neurotoxicity in control wild-type (control(wt)) mice, metallothionein double knockout (MTdko) mice, metal lothionein-transgenic (MTtrans) mice, and in cultured human dopaminergic (SK-N-SH) neurons to determine the neuroprotective potential of metallothionein against ONOO- induced neurodegeneration in Parkinson disease (PD). SIN-1-induced lipid peroxidation, reactive oxygen species synthesis, caspase-3 activation, and apoptosis were attenuated by metallothionein gene overexpression and augmented by metallothionein gene down-regulation. A progressive nigrostriatal dopaminergic neurodegeneration in weaver mutant (wv/wv) mice was associated with enhanced nitrite ion synthesis, metallothionein down-regulation, and significantly reduced dopamine synthesis and F-18-DOPA uptake as determined by high-resolution micropositron emission tomography neuroimaging. The striatal F-18-DOPA uptake was significantly higher in MTtrans mice than in MTdko and alpha-synuclein knockout (alpha-Syn(ko)) mice. These observations provide further evidence that nitric oxide synthase activation and ONOO- synthesis may be involved in the etiopathogenesis of PD, and that metallothionein gene induction may provide neuroprotection.
引用
收藏
页码:1576 / 1583
页数:8
相关论文
共 41 条
[11]   Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease [J].
Ebadi, M ;
Brown-Borg, H ;
El Refaey, H ;
Singh, BB ;
Garrett, S ;
Shavali, S ;
Sharma, SK .
MOLECULAR BRAIN RESEARCH, 2005, 134 (01) :67-75
[12]   The antioxidant properties of zinc and metallothionein [J].
Ebadi, M ;
Leuschen, MP ;
ElRefaey, H ;
Hamada, FM ;
Rojas, P .
NEUROCHEMISTRY INTERNATIONAL, 1996, 29 (02) :159-166
[13]   Coenzyme Q10 inhibits mitochondrial complex-1 down-regulation and nuclear factor-kappa B activation [J].
Ebadi, M ;
Sharma, SK ;
Wanpen, S ;
Amornpan, A .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2004, 8 (02) :213-222
[14]   EXPRESSION AND REGULATION OF BRAIN METALLOTHIONEIN [J].
EBADI, M ;
IVERSEN, PL ;
HAO, R ;
CERUTIS, DR ;
ROJAS, P ;
HAPPE, HK ;
MURRIN, LC ;
PFEIFFER, RF .
NEUROCHEMISTRY INTERNATIONAL, 1995, 27 (01) :1-22
[15]   Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease [J].
Ebadi, M ;
Sharma, SK .
ANTIOXIDANTS & REDOX SIGNALING, 2003, 5 (03) :319-335
[16]   Neuroprotective actions of selegiline [J].
Ebadi, M ;
Sharma, S ;
Shavali, S ;
El Refaey, H .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (03) :285-289
[17]  
Ebadi M, 1998, P W PHARMACOL SOC, V41, P155
[18]  
EBADI M, 1998, NEUROENDOCRINOL LETT, V18, P111
[19]  
EBADI M, 2002, FASEB J, V16
[20]  
EBADI M, 2005, PARKINSONS DIS, P479